## Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer

Jorge Ferrer PhD1; Shelly Hwang MD, MPH2; Kelly Hunt MD3; Daleela Dodge MD4, Anees Chagpar MD2, Stephen Grobmyer MD5, Stephen Karp MD5, Stephanie Valente DO6, Irene Wapnir MD7, Kate Smith MPH1, Elena Ramirez BS1, Thomas Bischof PhD8, David Strasfeld PhD1, David Lee MSc1, Barbara Smith MD, PhD9

1Lumicell, Inc.; 2Duke University Medical Center; 3MD Anderson Cancer Center; 4Hershey Medical Center; 5Yale-New Haven Health; 6Cleveland Clinic; 7Lashey Hospital and Medical Center; 8Stanford University Medical Center; 9Massachusetts General Hospital

### BACKGROUND

- Tumor-free margins are critical for local control in breast conserving surgery
- 20-40% of lumpectomy patients have positive margins that require surgical re-excision
- Tools are needed to identify residual tumor in patients at initial surgery
- The LUM Imaging System consists of intravenously injected LUM015 (protease-activated, fluorescence imaging agent), a hand-held wide field detector device and a decision software (proprietary algorithm)
- The LUM Imaging System is used to scan the surgical cavity walls intraoperatively after the resection of the main lumpectomy specimen

### STUDY DESIGN

- Non-randomized, prospective, multi-center feasibility study to train multiple sites on the proper use of the LUM Imaging System prior to the start of a pivotal study which will evaluate the safety and efficacy of the LUM Imaging System in reducing the positive margin rate in excised tissue during standard of care lumpectomies

### OBJECTIVES

- Train clinical staff and surgeons on integrating the LUM Imaging system into surgical practice
- Compare fluorescent intensity between in-vivo and ex-vivo images
- Establish site-specific workflow for labeling shaves by orientation
- Correlate LUM System saved images with histopathology results
- Collect safety and efficacy data

### METHODS

- Adult female breast cancer patients undergoing lumpectomies are being enrolled at community based and academic medical centers across the US
- Subjects are injected with LUM015 prior to surgery
- Surgeons perform standard of care lumpectomy
- LUM Imaging System is used intraoperatively and margins compared with pathology
- Shaves are obtained based on the LUM Imaging System
- Images of in-vivo tissue and ex-vivo tissue are recorded to measure the ratio of fluorescent intensity to verify that consistent tissue contact is made during lumpectomy cavity scanning
- Protocol-specific tools are used to maintain specimen orientation and naming to support study data integrity

### DISCUSSION

- LUM Imaging System training is intended to improve the quality and integrity of the data collected in the upcoming Pivotal clinical trial to evaluate the safety and efficacy of the LUM Imaging System. This System is also currently being evaluated in other cancer indications including gastrointestinal cancers, prostate cancer and brain cancer.

### ACKNOWLEDGEMENT

- This clinical trial is funded by the National Cancer Institute
- Lumicell Inc. holds the IDE and is the Sponsor of this study.
- The MGH Translational Clinical Research Center (TCRC) for support in design and execution of this clinical study

**Poster No. CT166**